Skip to main content

Table 2 Demographic and clinical characteristics of patients (N = 243)

From: Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians

Characteristic

 

Age, years

 

• Mean (SD)

40.69 (15.52)

• Range

12.0-78.0

• Median

41.0

• IQR

27.0, 52.0

Gender, n (%)

 

• Female

132 (54.32)

Ethnicity

 

• Caucasian

177 (72.84)

Body mass index, mg/kg2

 

• Mean (SD)

28.15 (6.85)

• Range

15.21-54.71

• Median

26.58

• IQR

23.34, 31.19

Body mass index, mg/kg2, n (%)

 

• Underweight (<18.5)

4 (1.72)

• Normal (18.5-24.9)

86 (36.91)

• Overweight (25–29.9)

73 (31.33)

• Obese (>30.0)

70 (30.04)

Smoking status, physican-reported, n (%)

 

• Current smoker

8 (3.29)

• Ex-smoker

43 (17.70)

• Never smoked

192 (79.01)

Physician-reported pack years, n (%)

 

• High (≥10)

29 (11.93)

• Low (<10)

22 (9.05)

• Never smoked

192 (79.01)

Lung function (FEV1)

 

• Mean (SD)

73.65 (17.80)

• Range

25.0-138.0

• Median

70.0

• IQR

63.5, 82.0

Frequency of asthma exacerbations in last 12 months

 

• Mean (SD)

1.08 (1.90)

• Range

0.0-14.0

• Median

0.0

• Range

0.0, 2.0

Frequency of asthma exacerbations in last 12 months, n (%)

 

• 0

134 (55.14)

• 1

44 (18.11)

• ≥2

65 (26.75)

Deyo Charlson Comorbidity Indexa [58]

 

• Mean (SD)

0.13 (0.53)

• Range

0-6

• Median

0

• IQR

0, 0

Most common concomitant conditions, n (%)

 

• Allergic rhinitis

115 (47.33)

• Gastroesophageal reflux disease

42 (18.26)

• Anxiety

36 (15.65)

• Obesity

27 (11.74)

• Cardiovascular diseasec

15 (6.17)

• None

45 (18.52)

Physician managing patient’s asthma, n (%)

 

• Primary care- only

69 (28.40)

• Specialist-led

174 (71.60)

Morisky Medication Adherence Scale, n (%)

 

• Low

97 (39.92)

• Medium

89 (36.63)

• High

57 (23.46)

Asthma Control Test

 

• Mean (SD)

19.91 (3.94)

• Range

6-25

• Median

20

• IQR

18, 23

Asthma Control Test, n (%)

 

• 5-19 (Not well controlled)

99 (40.74)

• ≥20 (Well controlled)

144 (59.26)

Jenkins Sleep Evaluation Questionnaireb

 

• Mean (SD)

4.02 (4.53)

• Range

0-20

• Median

3

• IQR

0, 6

Jenkins Sleep Evaluation Questionnaireb, n (%)

 

• 0

76 (31.28)

• 1-5

97 (39.92)

• 6-10

44 (18.11)

• 11-15

21 (8.64)

• 16-20

5 (2.06)

EuroQol-5D-3L

 

• Mean (SD)

0.91 (0.14)

• Range

0.27-1

• Median

1

• IQR

0.84, 1

  1. aConditions as described by Deyo–Charlston index [57] are mapped from as many as 10 reported ICD-9-CM secondary diagnosis codes. A single summary cumulative value is represented. A score of 0 represents no comorbidities. Out of the 17 conditions, this research could accommodate 12 including: myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, diabetes mellitus, cerebrovascular disease, COPD, connective tissue disease, mild liver disease, ulcer diagnosis, moderate or severe renal disease, any malignancy including lymphoma and leukemia, and acquired immunodeficiency syndrome. Missing data for a specific variable on the physician-reported form or the patient-reported from resulted in exclusion of the subject from the individual analysis for that variable but inclusion on all analyses for which data were not missing
  2. bHigher score on the JSEQ indicates greater levels of sleep disturbance
  3. cCardiovascular disease excludes hypertension and hyperlipidaemia. FEV1, forced expiratory volume in 1 s; IQR, interquartile range; SD, standard deviation